HeartFlow, Inc. (HTFL)
| Market Cap | 2.48B |
| Revenue (ttm) | 191.42M +40.6% |
| Net Income | -111.83M |
| EPS | -1.97 |
| Shares Out | 86.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,469,509 |
| Open | 29.15 |
| Previous Close | 28.85 |
| Day's Range | 28.50 - 30.55 |
| 52-Week Range | 20.13 - 41.22 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 37.00 (+28.43%) |
| Earnings Date | May 14, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heart... [Read more]
Financial Performance
In 2025, HeartFlow's revenue was $176.03 million, an increase of 39.92% compared to the previous year's $125.81 million. Losses were -$116.79 million, 21.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for HTFL stock is "Buy." The 12-month stock price target is $37.0, which is an increase of 28.43% from the latest price.
News
Heartflow price target lowered to $37 from $43 at Canaccord
Canaccord lowered the firm’s price target on Heartflow (HTFL) to $37 from $43 and keeps a Buy rating on the shares. The firm said Heartflow reported a solid beat-and-raise, with…
Heartflow price target raised to $37 from $35 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Heartflow (HTFL) to $37 from $35 and keeps an Overweight rating on the shares. The firm notes the company…
Heartflow reports Q1 EPS (32c), consensus (17c)
Reports Q1 revenue $52.59M, consensus $49.7M. “Heartflow (HTFL) entered 2026 with unprecedented momentum, expanding the category leadership we established over the last several years,” said John Farqu...
Heartflow raises FY26 revenue view to $228M-$232M from $218M-$22M
Consensus $220.38M. Narrows FY26 gross margin view to 81% from 80%-81%.
HeartFlow Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 41% year-over-year to $52.6 million, driven by strong FFRCT and Plaque adoption, with gross margin rising to 80.5%. Full-year guidance was raised for both total and Plaque-specific revenue, and the platform expanded with PCI Navigator and a growing AI data asset.
HeartFlow Earnings release: Q1 2026
HeartFlow released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
HeartFlow Quarterly report: Q1 2026
HeartFlow has published its Q1 2026 quarterly earnings report on May 14, 2026.
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the firs...
Heartflow initiated with an Outperform at William Blair
William Blair initiated coverage of Heartflow (HTFL) with an Outperform rating and no piece target. The company’s AI-enabled, non-invasive platform changes the heart attack paradigm, providing actiona...
HeartFlow Proxy statement: Proxy filing
HeartFlow filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
HeartFlow Proxy statement: Proxy filing
HeartFlow filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial r...
Heartflow files patent infringement lawsuit against Cleerly
Heartflow (HTFL) announced that it has filed a patent infringement lawsuit against Cleerly in the United States District Court for the Eastern District of Texas. The complaint seeks permanent injuncti...
Heartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Hea...
Heartflow price target lowered to $35 from $40 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on Heartflow (HTFL) to $35 from $40 and keeps an Overweight rating on the shares. The firm view s the company’s…
Heartflow price target raised to $43 from $40 at Canaccord
Canaccord raised the firm’s price target on Heartflow (HTFL) to $43 from $40 and keeps a Buy rating on the shares. The firm said HeartFlow reported a solid Q4 beat…
HeartFlow Earnings Call Transcript: Q4 2025
Q4 revenue grew 40% year-over-year to $49.1M, with strong FFRct and Plaque Analysis adoption and record installed base expansion. FY2026 guidance projects 24–26% revenue growth, margin expansion, and accelerating plaque contribution, supported by new product launches and favorable reimbursement trends.
HeartFlow Annual report: Q4 2025
HeartFlow has published its Q4 2025 annual report on March 18, 2026.
HeartFlow Earnings release: Q4 2025
HeartFlow released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Heartflow reports Q4 EPS (29c), consensus (16c)
Reports Q4 revenue $49.13M, consensus $46.5M. “Our strong fourth quarter performance concluded a record year for Heartflow (HTFL),” said John Farquhar, President and CEO of Heartflow. “The acceleratin...
Heartflow sees FY26 revenue $218M-$22M, consensus $212.94M
Sees FY26 gross margin 80%-81%.
Heartflow announces clinical evidence, landmark registry launch
Heartflow (HTFL) announced new clinical evidence and a landmark registry launch that together advance the company’s vision of transforming CAD management across every stage of the patient journey. At ...
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
Three presentations at ACC reinforce Heartflow's AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGAT...
HeartFlow Transcript: Morgan Stanley Technology, Media & Telecom Conference 2026
AI-powered platform for coronary artery disease diagnosis is expanding rapidly, leveraging a proprietary, FDA-cleared, and reimbursed technology suite. Key growth drivers include Plaque Analysis, new product launches, and entry into the high-risk asymptomatic market, supported by a robust clinical and data infrastructure.
Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of mana...